Progress and prospects of chimeric antigen receptor T cells immunocellular therapy
10.16098/j.issn.0529-1356.2025.03.017
- VernacularTitle:嵌合抗原受体T细胞免疫细胞疗法的应用进展与前景
- Author:
Jun XIN
1
;
Bai-Chuan WANG
;
Run XIAO
Author Information
1. 天津大学医学院,天津 300072;中国科学院杭州医学研究所创新药物与精准治疗中心,杭州 310018;浙江省肿瘤医院浙江省肿瘤智能诊断与分子技术诊治技术研究中心,杭州 310022
- Keywords:
Tumor Immunotherapy;
Chimeric antigen receptor;
T cell;
Precision medicine;
Immunocellular therapy
- From:
Acta Anatomica Sinica
2025;56(3):371-380
- CountryChina
- Language:Chinese
-
Abstract:
Tumor is the main lethal type of major diseases that human beings are facing nowadays.Traditional therapies,such as chemotherapy,surgery,radiotherapy,etc,have been the mainstay of tumor treatment for a long time,and still have their own limitations in terms of effectiveness.In recent years,immunotherapy for tumors has attracted much attention with the rise of strategies such as immune checkpoint inhibitors,chimeric antigen receptor T-cell(CAR-T)relay therapy,and anti-tumor vaccines.Among them,CAR-T cell therapy,as a breakthrough tumor immunotherapy method,can precisely target tumors at the cellular and molecular levels by modifying the patient's own T cells to express recombinant antigen receptors targeting specific tumor antigens,breaking the restriction of the major histocompatibility complex(MHC)of the natural T cells themselves.It can precisely target tumors at the cellular and molecular levels,and thus can efficiently and specifically identify and kill cancer cells,providing a new perspective for treatment.Since the approval of the first CAR-T therapy by the US Food and Drug Administration(FDA)in 2017,in addition to still maintaining significant advantages in the field of classical multiple hematologic malignancies,it has also made outstanding progress in the treatment and clinical trials of some solid tumors and autoimmune diseases,among others.This paper will briefly review the current principles,applications,challenges and directions of development of CAR-T technology.
